骨显像评价^(89)Sr治疗前列腺癌骨转移的效应  

To evaluate the treating effect of strontium-89 (^(89)Sr) on prostate cancer bone metastases by bone imaging

作　　者：马玉波[1] 刘平安[1] 顾爱春[1] 徐枫[1] 戴继灿[2] 

机构地区：[1]上海交通大学医学院附属第九人民医院核医学科,上海200011 [2]上海交通大学医学院附属仁济医院泌尿外科

出　　处：《中国男科学杂志》2008年第6期24-26,共3页Chinese Journal of Andrology

摘　　要：目的了解骨显像评价89Sr对前列腺癌骨转移的治疗效果。方法通过骨显像确认骨转移的53例前列腺癌患者,静脉给药89Sr治疗,剂量1.48~2.22MBq(40~60μC)/kg,3~6个月后复查骨显像,与治疗前对比。结果(1)治疗后39(73.6%)例骨转移灶数目较治疗前明显减少或消失,10(18.9%)例稳定,4(7.5%)例恶化;(2)骨转移灶代谢活性即ROI比值(T/NT),由治疗前的(4.8±3.3)下降到(3.2±2.7);(3)部分病例可发现新生转移灶,范围扩大,核素浓集程度加深,临床改善和预后不佳。结论骨显像评价89Sr治疗前列腺癌骨转移,客观、全面,对预后评价也有较高的临床价值。Objective To evaluate the treating effect of strontium-89 （^89Sr） on bone metastases of prostate cancer by bone imaging. Methods 53 cases of prostate cancer bone metastases proved by bone imaging were treated with intravenous injection of ^89Sr 1.48 to 2.22 MBq （40-60 μ Ci）/kg, they were checked again by bone imaging 3 to 6 months later. The pre- and post-imagings were comparatively analyzed. Results （1） The number of focus dacreased or disappeared distinctly or disappeared in 39 patients （73.6%） after therapy, tranquilized in 10 patients（18.9%） exacerbate in 4 patients（7.5%）. （2）Value of ROI（T/NT） decreased from （4.8±3.3） to （3,2±2.7） after treatment. （3） Exacerbation Such as appearance of new focus, area of focus extended, level of nuclide aggregation intersive and poor prognosis was found in soml cases.

关 键 词：骨显像 前列腺肿瘤 放射疗法 肿瘤转移 锶放射性同位素 

分 类 号：R817.5[医药卫生—影像医学与核医学] R737.25[医药卫生—放射医学]